Arrowhead Pharmaceuticals, Inc.(ARWR): For the most recent quarter end, Arrowhead Pharmaceuticals, Inc. reported Annual Earnings of $-0.17. Based on the filings, last years Annual Earnings was, $-1.31. For the most recent quarter end, ARWR reported a surprise Earnings per Share of 5.56% . The consensus estimate for current quarter is $-0.12 and for the current fiscal year, the estimate is $-0.49. For the Next fiscal year, the estimate is $-0.66 based on the consensus. Pasadena based Arrowhead Pharmaceuticals, Inc. Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on May 09, 2017.
Arrowhead Pharmaceuticals, Inc. has received $-0.12 as the consensus Earnings Estimate for the Quarter ending on Mar 2017 ,According to the estimate provided by 3 Financial Advisor in the Stock Trading Firms. Among 3 Analysts, Bottom line EPS Estimate for the current quarter is $-0.16 while the top line estimate is $-0.1 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 64.76%. Arrowhead Pharmaceuticals, Inc. reported better than expected with a surprise EPS of 5.56% or $0.01 during its most recent quarterly earnings. The Actual EPS was $-0.17 compared to the Estimated EPS of $-0.18. According to the corporate earnings calendar, Arrowhead Pharmaceuticals, Inc. will release next earnings on May 09, 2017 with an estimated EPS consensus of $-0.12. Based on the consensus of stock financial advisors the stock has a price target of $2.67. Current year estimate on EPS consensus is $-0.49.
For Dividend Investing Stock Market Traders Arrowhead Pharmaceuticals, Inc. has a Dividend Yield of 0% with an Annual Dividend of $0.
Arrowhead Research Corp Last issued its quarterly earnings results on Aug 9, 2016. The company reported $-0.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.04. Analyst had a consensus of $-0.36. The company had revenue of $39.58 million for the quarter, compared to analysts expectations of $.05 million. The companys revenue was down -68.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.27 EPS.
Company has reported several Insider transactions to the SEC, on Oct 18, 2016, Douglas B Given (director) sold 12,000 shares at 6.72 per share price.On Aug 24, 2016, Kenneth Allen Myszkowski (Chief Financial Officer) sold 20,000 shares at 8.00 per share price.On Jan 14, 2015, Mauro Ferrari (director) purchased 2,300 shares at 6.90 per share price.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) witnessed a decline in the market cap on Wednesday as its shares dropped 0.47% or 0.01 points. After the session commenced at $2.16, the stock reached the higher end at $2.18 while it hit a low of $2.08. With the volume soaring to 841,135 shares, the last trade was called at $2.14. The company has a 52-week high of $8.22. The company has a market cap of $160 million and there are 74,569,706 shares in outstanding. The 52-week low of the share price is $1.2.
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The companys proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.